EUVIMEDEUVIMED entdecken
Crossref

Abstract 82: CTX340 TM , a CRISPR-CAS9 Gene Editor Targeting AGT, Achieves Robust and Durable Blood Pressure Control in Spontaneously Hypertensive Rats While Preserving Blood Pressure in Normotensive Non-Human Primates

Kenneth Drombosky, Nikita Joshi, Harshi Gangrade, Viktoriia Kyrychenko, Jennifer Nielsen, Jason Duran, NAIMISH PATEL, Iqra Anwar, Conrad Hodgkinson, Victor J Dzau

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.82 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Kenneth Drombosky und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inhibition of the renin-angiotensin-aldosterone system (RAS) is effective in treating essential hypertension. However, therapies typically require lifelong daily administration. Poor adherence remains a major barrier to sustained blood pressure control. An ideal therapy would be a single treatment which provides long-term sustained blood pressure control. We report a novel vivo gene-editing therapy for hypertension, CTX340™, which targets the angiotensinogen (AGT) gene to provide durable blood pressure reduction following a single administration. Hypothesis: Disruption of hepatic AGT production by CTX340 TM durably decreases angiotensin production and systemic RAS activation, resulting in sustained lowering of arterial blood pressure and attenuation of adverse cardiac remodeling.

Methods

CTX340 TM is composed of a lipid nanoparticle (LNP) encapsulating a Cas9 nuclease mRNA and a sgRNA targeting the AGT gene in hepatocytes. CTX340 TM was evaluated in spontaneously hypertensive rats (SHRs) and in normotensive non-human primates (NHPs, GLP).

Results

In SHRs, a single treatment of surrogate CTX340 TM achieved saturating liver gene editing, resulting in marked suppression of plasma AGT levels and downstream angiotensin I and II (3.2-8.7 fold, p

Zitieren

APA

Drombosky, K., Joshi, N., Gangrade, H., Kyrychenko, V., Nielsen, J., Duran, J., PATEL, N., Anwar, I., Hodgkinson, C., & Dzau, V. J. (2026). Abstract 82: CTX340 TM , a CRISPR-CAS9 Gene Editor Targeting AGT, Achieves Robust and Durable Blood Pressure Control in Spontaneously Hypertensive Rats While Preserving Blood Pressure in Normotensive Non-Human Primates. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.82

Vancouver

Drombosky K, Joshi N, Gangrade H, Kyrychenko V, Nielsen J, Duran J, et al. Abstract 82: CTX340 TM , a CRISPR-CAS9 Gene Editor Targeting AGT, Achieves Robust and Durable Blood Pressure Control in Spontaneously Hypertensive Rats While Preserving Blood Pressure in Normotensive Non-Human Primates. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.82

BibTeX
@article{Drombosky2026,
  author = {Drombosky, Kenneth and Joshi, Nikita and Gangrade, Harshi and Kyrychenko, Viktoriia and Nielsen, Jennifer and Duran, Jason and PATEL, NAIMISH and Anwar, Iqra and Hodgkinson, Conrad and Dzau, Victor J},
  title = {Abstract 82: CTX340 TM , a CRISPR-CAS9 Gene Editor Targeting AGT, Achieves Robust and Durable Blood Pressure Control in Spontaneously Hypertensive Rats While Preserving Blood Pressure in Normotensive Non-Human Primates},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.82}
}
Kostenlos starten →